Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia

SAN FRANCISCO, February 10, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that... Biopharmaceuticals, Neurology, FDAAmarantus BioScience, Eltoprazine, dyskinesia, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news